Form 4: Alnylam Pharmaceuticals Executive Pushkal Garg Reports Stock Transactions
SEC Form 4
CMO & EVP Dev & Med Affairs Pushkal Garg reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- Pushkal Garg, CMO & EVP Dev & Med Affairs at Alnylam Pharmaceuticals, filed a Form 4 detailing stock transactions.
- On February 27, 2025, 1,908 restricted stock units (RSUs) vested.
- These RSUs were granted on February 27, 2023, and vest ratably over three years.
- Following the vesting, shares were sold to cover tax withholding obligations.
- Sales occurred on February 28, 2025, at prices ranging from $236.51 to $244.32.
- A total of 934 shares were sold on February 28, 2025.
- After these transactions, Garg directly owns 12,962 shares of common stock.
- Garg also indirectly owns 431 shares through a managed account and 250 shares through a trust where his spouse is co-trustee.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions related to executive compensation and doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
Form 4 filings are routine disclosures for corporate insiders and provide transparency into their trading activities. This filing indicates standard compensation practices involving stock-based awards and tax-related sales.
Comparison to Industry Standards
- Stock sales to cover tax obligations upon RSU vesting are a common practice among executives in publicly traded companies, including those in the pharmaceutical industry.
- Companies like Amgen, Gilead, and Biogen also see similar insider transactions related to equity compensation.
Key Dates
| Date | Description |
|---|---|
| 02/27/2023 | Date of grant for 5,724 restricted stock units vesting ratably over three years. |
| 02/27/2025 | Vesting date of 1,908 restricted stock units. |
| 02/28/2025 | Date of stock sales to cover tax obligations. |
| 03/03/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.